



Silence Therapeutics to Participate in September Investor Conferences

9/6/2023

LONDON--(BUSINESS WIRE)-- Silence Therapeutics plc, Nasdaq: SLN ("Silence" or the "Company"), an experienced and innovative biotechnology company committed to transforming people's lives by silencing diseases through precision engineered medicines, today announced that Company management will participate in the following investor conferences and invited investors to participate by webcast.

- Morgan Stanley Global Healthcare Conference Fireside Chat on Monday, September 11, 2023 at 9:20am EDT
- HC Wainwright Global Investment Conference Fireside Chat on Tuesday, September 12, 2023 at 10am EDT
- Cantor Global Healthcare Conference Formal Presentation on Wednesday, September 27, 2023 at 4:10pm EDT

The webcasts can be accessed via the Investors section of the Silence website at www.silence-therapeutics.com. An archived replay of the webcasts will be available following the conference.

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include zerlasiran designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address hematological diseases. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit <https://www.silence-therapeutics.com/>.

View source version on **businesswire.com**: <https://www.businesswire.com/news/home/20230906810931/en/>

Enquiries:

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

Tel: +1 (646) 637-3208

Source: Silence Therapeutics plc